Combined Study of ATrial Strain & Voltage by High Density Mapping in Young

Status Not yet recruiting

Clinical Trial Summary

Atrial The treatment of atrial fibrillation (AF) includes 2 axes: the prevention of the cardio-embolic risk and rhythm control. The possibilities for this control are antiarrhythmic drugs and, above all, catheter ablation, an interventional cardiology technique which consists in treating the areas responsible for the initiation and perpetuation of AF by applying radiofrequency energy or cryotherapy to the myocardial tissue. Limited research has been done on the combination of different parameters to manage AF, especially during the initial stage of the disease. A translational and multimodal approach could make it possible to better characterize this pathology and thus, help to adjust the therapeutic management for the patients. The combined analysis of regional electrophysiological, morphological, and functional parameters of the left atrium could make it possible to better detect early atrial cardiomyopathy and predict recurrences of atrial fibrillation.

Clinical Trial Description

The electrophysiological substrate for patients with persistent atrial fibrillation is heterogeneous with areas of atrial myocardium of low voltage amplitudes and areas of rapid fragmented signals in arrhythmia. The targets of ablation treatment in these cases are currently poorly defined. Several promising strategies have emerged, such as the isolation of fibrotic areas, low voltage. An integration analysis of regional electrophysiological, morphological, and functional parameters of the left atrium, therefore, open up a new area of research that has not been studied to date and could help to better guide the therapeutic management of patients with AF. The study aims to assess the association between regional and global myocardial strain abnormalities on magnetic resonance imaging (MRI) and the amplitude of the atrial intracardiac electrical potential, in young subjects with symptomatic AF. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05565183
Study type	Interventional
Source	Assistance Publique - Hôpitaux de Paris
Contact	Nicolas BADENCO, MD
Phone	+33 1 42 16 29 76
Email	nicolas.badenco@aphp.fr
Status	Not yet recruiting
Phase	N/A
Start date	October 2022
Completion date	November 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05970120` - A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter	N/A
Recruiting	`NCT06014996` - Comparison of PFA vs. RFA in Patients With Symptomatic Paroxysmal Atrial Fibrillation.	N/A
Completed	`NCT03624881` - Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU)	Phase 4
Recruiting	`NCT05416086` - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study	N/A
Recruiting	`NCT05905835` - Treatment of PAF With the Synaptic System	N/A
Active, not recruiting	`NCT05618340` - PFA for Paroxysmal Atrial Fibrillation	N/A
Active, not recruiting	`NCT05534581` - SINGLE SHOT CHAMPION	Phase 4
Not yet recruiting	`NCT05024630` - Renal Denervation and pUlmonary Vein isolAtion With cryoabLation on Patients With Atrial Fibrillation and hypErtension	N/A
Completed	`NCT02610803` - Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke	N/A
Completed	`NCT01913522` - Cryoballoon vs. Irrigated Radiofrequency Catheter Ablation: Double Short vs. Standard Exposure Duration	N/A
Withdrawn	`NCT01917981` - Testing the Accuracy of a Personal Heart Rhythm Monitor to Detect Prolonged Paroxysmal Atrial Fibrillation	Phase 3
Terminated	`NCT01925885` - Focal Impulse and Rotor Modulation Ablation Trial for Treatment of Paroxysmal Atrial Fibrillation (FIRMAT-PAF)	N/A
Completed	`NCT01842529` - Botulinum Toxin Injection in Epicardial Fat Pads To Treat Atrial Fibrillation After Cardiac Surgery	Phase 2
Completed	`NCT01693107` - Atrial Fibrillation Force Contact Ablation Study
Completed	`NCT00971204` - Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation	Phase 2
Completed	`NCT05043883` - Automated Assessment of PVI Using a Novel EP Recording System	N/A
Recruiting	`NCT05172765` - Biomarker-Guided Optimization of Transcutaneous Vagal Stimulation for Atrial (BiG tVNS-AF)	N/A
Recruiting	`NCT04529785` - Added Value of Vein of Marshal Ethanol Infusion Compared to Superior Vena Cava Isolation Alone in Patients Undergoing Repeat Ablation for Recurrent Paroxysmal Atrial Fibrillation Despite Durable PV Isolation	N/A
Completed	`NCT04022954` - HD Mapping of Atrial Fibrillation in Asia Pacific
Completed	`NCT00964392` - NAVISTAR® THERMOCOOL® Catheter Post Approval Registry	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Combined Study of ATrial Strain and Voltage by High Density Mapping in Young Patients With Atrial Fibrillation. — CATS-AF

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms